Back to Hepatology
Hepatologyv2015Evidence-Based

ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)

Predicts survival in hepatocellular carcinoma patients based on serum albumin and bilirubin concentrations

Clinical Input Parameters

g/L
Range: 1 — 6 g/L
μmol/L
Range: 3 — 500 μmol/L
Clinical Assessment
Awaiting Parameters
albi score
—score
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hepatology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

ALBI = (log10 bilirubin × 0.66) + (albumin × -0.085), where bilirubin is in μmol/L and albumin in g/L

Clinical Pearls & Practice Notes

  • Alternative to Child-Pugh grade without subjective variables like ascites and encephalopathy
  • Uses only objective laboratory measures of liver function
  • Developed from international collaboration involving 1,313 Japanese HCC patients
  • Validated across multiple geographical regions and clinical situations
  • ALBI Grade 1: ≤-2.60, Grade 2: >-2.60 to ≤-1.39, Grade 3: >-1.39
  • Survival depends on tumor stage, liver function, and performance status
  • Applicable to HCC patients with or without underlying cirrhosis

Evidence & Literature Citations

  1. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8. doi: 10.1200/JCO.2014.57.9151.
  2. Hiraoka A, Michitaka K, Kumada T, et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6(4):325-336. doi: 10.1159/000479984.
  3. Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017;96(24):e7142. doi: 10.1097/MD.0000000000007142.

Score Interpretation Ranges

Grade 1-10 – -2.6 pts

Best prognosis

Grade 2-2.6 – -1.39 pts

Intermediate prognosis

Grade 3-1.39 – 10 pts

Poorest prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.